'Resurrection of the Christ' Release Pushed at Lionsgate, Replaced by Johnny Depp's 'Day Drinker'

Lionsgate shifted its 2027 release slate, moving Johnny Depp’s "Day Drinker" into a March 26, 2027 slot and pushing Mel Gibson’s "The Resurrection of the Christ" to May 6, 2027, with Part Two now set for May 25, 2028. The move preserves marquee Easter/holiday positioning while spacing the two-part religious sequel a year apart rather than 40 days apart. The article is primarily a release-date update with limited immediate financial impact.

Analysis

The slate shift reduces the odds of Lionsgate accidentally cannibalizing its own premium religious tentpole with a second event title in the same demand window. Staggering the two halves by a full year should improve pricing power on the first installment, but it also transfers execution risk into a much longer financing and marketing period, which can amplify downside if the first film underperforms or if Gibson’s brand weakens further by release.

The more interesting second-order effect is competitive: moving a Depp-led genre title into an Easter-adjacent slot suggests Lionsgate is willing to trade away direct faith-audience overlap for a broader four-quadrant counterprogramming bet. That creates a cleaner runway for the religious sequel, but it also puts pressure on the studio to win on both ends of the slate rather than relying on one event film to carry the season. If the religious title lands, it could pull disproportionate ancillary revenue through premium screens, international faith markets, and long-tail home entertainment, but if it disappoints, the stretched cadence means the franchise thesis gets repriced over multiple quarters instead of one.

Consensus is likely underestimating how much this is a distribution and calendar-management story rather than a pure content story. The real vulnerability is timing risk: Easter-adjacent release dates are high-variance, and any slippage in VFX, rating, or marketing delivery would push the film into a much less favorable window and compress the implied upside by 20-30% based on typical holiday-weekend box office elasticity. For the broader sector, the move reinforces how scarce “event” windows are; studios with crowded 2027 slates may be forced into less optimal dates, increasing dispersion between top- and bottom-quartile theatrical outcomes.

Key Decisions for Investors

• Stay neutral on Lionsgate equity until the 2027 slate is de-risked; if available, favor buying downside protection into the first-release marketing ramp rather than chasing pre-release optimism.
• Long premium-exposure beneficiaries versus theatrical risk: consider a pair trade long IMAX / short a weaker mid-cap studio name if box office concentration into event titles continues to widen over the next 6-12 months.
• For event-driven upside, buy a limited-risk call spread on Lionsgate 6-9 months before the first film’s P&A spend peaks; the setup improves only if pre-sales and trailer response validate the religious-audience thesis.
• Watch for schedule drift or rating issues; if the first film slips by even one quarter, reassess the entire duology at 20-30% lower probability-weighted box office value.